BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

$94.10-0.08 (-0.08%)

Delayed as of 25 Nov 2024, 01:54 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BPMC Price Action

Last 7 days

6.2%

Last 30 days

11.6%

Last 90 days

-0.4%

Trailing 12 Months

40.6%

BPMC RSI Chart

BPMC Valuation

Market Cap

6.0B

Price/Earnings (Trailing)

-46.72

Price/Sales (Trailing)

13.77

EV/EBITDA

-71.64

Price/Free Cashflow

-23.88

BPMC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BPMC Fundamentals

BPMC Revenue

Revenue (TTM)

434.4M

Rev. Growth (Yr)

126.61%

Rev. Growth (Qtr)

-7.22%

BPMC Earnings

Earnings (TTM)

-128.1M

Earnings Growth (Yr)

57.91%

Earnings Growth (Qtr)

-12.57%

BPMC Profitability

EBT Margin

-29.33%

Return on Equity

-40.89%

Return on Assets

-10.67%

Free Cashflow Yield

-4.19%

BPMC Investor Care

Shares Dilution (1Y)

4.50%

Diluted EPS (TTM)

-2.12

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	282.2M	362.8M	434.4M	0
2023	204.6M	225.6M	216.2M	249.4M
2022	221.2M	230.5M	272.3M	204.0M
2021	640.3M	486.9M	333.5M	180.1M
2020	71.9M	312.5M	553.1M	793.7M
2019	50.0M	55.5M	61.0M	66.5M
2018	27.2M	33.0M	38.7M	44.5M
2017	26.8M	25.6M	27.5M	21.4M
2016	17.6M	22.0M	24.7M	27.8M
2015	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Kathryn Haviland
WEBSITE	blueprintmedicines.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	660

Blueprint Medicines Corp Frequently Asked Questions

What is the ticker symbol for Blueprint Medicines Corp? What does BPMC stand for in stocks?

BPMC is the stock ticker symbol of Blueprint Medicines Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blueprint Medicines Corp (BPMC)?

As of Fri Nov 22 2024, market cap of Blueprint Medicines Corp is 5.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers.

Is Blueprint Medicines Corp a good stock to buy?

The fair value guage provides a quick view whether BPMC is over valued or under valued. Whether Blueprint Medicines Corp is cheap or expensive depends on the assumptions which impact Blueprint Medicines Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BPMC.

What is Blueprint Medicines Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, BPMC's PE ratio (Price to Earnings) is -46.72 and Price to Sales (PS) ratio is 13.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BPMC PE ratio will change depending on the future growth rate expectations of investors.